Ohh Wow! Last Tip Still Going Up...

[UNSUBSCRIBE]( So as we are all watching NASDAQ: LGVN.... We saw it open up with strength at $6.82... It then dipped as low as $6.48 and has just been swinging up and down but now seems like it could be building MOMENTUM! Can we see it today go RED to GREEN? Like with the last Tip, remember these are long term... Actually the last one is up another 6% today hitting $5.41 from under $4 when we first alerted it (representing a total possible gains of OVER 27% in just a little over a week! So with NASDAQ: LGVN we could potentially be seeing some moves this week, all I can say is WATCH LGVN! Previous Email with Full Report Below: LGVN may be the biggest biotech breakthrough company hiding in the market right now.... Greetings All, Nobody likes to get older... as we age, we become disproportionally affected by chronic conditions and poor health. Many biotech companies are racing to develop an anti-aging cure and therapies that may help combat chronic diseases that are associated with aging. Did you know that there is vast potential for healthy aging to be achieved through regenerative medicine approaches? Regenerative medicine is the BIGGEST medical breakthrough in natural medicine. There are also real opportunities for regenerative medicine in the treatment of COVID-19. While the world is busy focused on geopolitical events, cryptocurrencies, and interest rates, paying close attention to breakthroughs in regenerative medicine, treatments of disease, and understanding issues of aging could be incredibly advantageous right now. [Image]( That's what brings us to today's emerging NASDAQ company... [Image]( [www.longeveron.com]( Longeveron, Inc. NASDAQ: LGVN LGVN is a growing biotech company that was founded on the premise that the very cells within our bodies whose primary function is to repair, restore and regenerate damaged tissue and organs may be developed into a safe and effective “off-the-shelf” cell therapy. This is therapy that could treat chronic aging-related diseases and other life-threatening conditions, to improve health span, and to extend longevity. Therapeutic indications under clinical study include Alzheimer's disease. The condition affects more than 6.2 million people in the US alone; it’s also the most common form of dementia and is the [sixth leading cause of death in America!]( Continue reading to see why LGVN should be on your radar as the company pioneers a therapy that may help to change the world! [Image]( As we age, our endogenous repair mechanisms become less effective, leading to chronic disease and poor health. Medical innovations that could transform treatment for billions of people living with chronic diseases have become imperative. LGVN is a clinical-stage biotechnology company that is developing cellular therapies for chronic diseases associated with aging and other life-threatening conditions. With an era defining product line, the company is aiming to disrupt the trillion-dollar healthcare sector! The company's lead investigational product, Lomecel-B™, is derived from culture-expanded medicinal signaling cells (MSCs) isolated from the donated bone marrow of young healthy adults. These multipotent MSCs have special therapeutic properties, including homing to sites of inflammation and tissue damage, and stimulating tissue repair and organ maintenance, as well as modulation of immune system function. By harnessing these properties from allogeneic cells obtained from young healthy donors, LGVN's goal is to develop safe and effective cell therapy for some of the most difficult diseases and conditions associated that are associated with aging! [Image]( Life expectancy has substantially increased over the past century as a result of medical and public health advancements. This increase in longevity has however not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging. This period is known as one's healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. LGVN's clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes. The company's therapeutic indications currently under clinical study are: • Hypoplastic Left Heart Syndrome (HLHS) - a congenital birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing. As a consequence, babies born with this condition have severely diminished systemic blood flow, which requires children to undergo a complex, three stage heart reconstruction surgery process over the course of the first 5 years of their lives. LGVN is testing Lomecel-B as a potential combinatorial therapy candidate to surgical intervention for HLHS. The scientific goal underlying this study builds on surgical advances of the past thirty years, and is intended to address remaining obstacles to improving transplant-free survival in HLHS patients. In fourth quarter 2021, the U.S. FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation to Lomecel-B for the treatment of infants with HLHS! • Alzheimer’s Disease - which affects over 5 million Americans, is a neurodegenerative disorder that leads to progressive memory loss and death. There are few drugs available for treating Alzheimer’s disease, and none that affect the long-term progression of the disease. LGVN has partnered with the Alzheimer’s Association to advance clinical research using a cell therapy approach to treating this devastating disease! • Aging Frailty - Why do some age well while others become frail? As a society, we are living longer than we did 100 years ago, but longevity comes with longer period of living with disability. Can we extend the period of time that we live in relatively good health, free of chronic disease, dependence and disability, a period known as “healthspan”? Individuals with Aging Frailty are at higher risk for adverse health outcomes such as falls, fractures, loss of independence, susceptibility to infection, institutionalization, hospitalization and death. LGVN is leading the efforts to develop a regenerative medicine approach for intervention and treatment of Aging Frailty! • Metabolic Syndrome - a multifactorial condition characterized by cluster of conditions that increases the risk heart disease, stroke and diabetes. These conditions include obesity around the central area of the body, high blood sugar, dyslipidemia (elevated cholesterol or fats in the blood) and hypertension (high blood pressure). As part of the company's Aging Frailty program, LGVN is exploring the effect of cell therapy on cluster of risk factors associated with the Metabolic Syndrome. • Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or Influenza - LGVN is researching the potential for cell therapy to treat the deadly condition of Acute Respiratory Distress Syndrome, or ARDS. ARDS occurs when fluid builds up in the lungs (sometimes referred to as “wet lung”), which impairs the ability for oxygen to get into the body and blood stream. ARDS can be caused by illnesses such as influenza or COVID-19 infection. Because age is one of the primary risk factors for infection with coronavirus and influenza, and for the development of ARDS, it is imperative that safe and effective treatments are developed to address this often fatal condition. The company is conducting a Phase 1 trial for ARDS associated with influenza and COVID-19 infection. Check out some of these alarming facts: - ARDS occurs in about 150,000 patients per year, can result in both short-term severe consequences (e.g., prolonged and expensive hospitalization, and death), and long-term debilitating consequences (e.g., severe lung fibrosis and pulmonary dysfunction). ARDS due to viral infection is particularly devastating to those with Aging Frailty, and is especially well-appreciated in the context of the COVID-19 pandemic, in which approximately 80% of deaths have occurred in people aged 65 and older. There are currently limited treatment options for ARDS beyond supportive palliative care, making ARDS a “rare disease or condition” under the FDA’s Orphan Drug Act definition, and an extremely important unmet medical need. - There are no approved therapies for the Metabolic Syndrome, aside from symptomatic treatments. The incidence of this syndrome has reached epidemic proportions and is estimated to impact approximately 35% of the total U.S. population aged 18 and older, or over 80 million people. - Frail individuals have an increased risk of poor clinical outcomes such as hospitalization, dependency, disability and/or death. Signs and symptoms of frailty include reduced activity, slowness, involuntary weight loss, weakness, and fatigue. Additionally, there is a connection between frailty and chronic inflammation in the body. Frail elderly patients place significant demand for healthcare services and there are no approved therapeutics for the condition. [Image]( Targeting Alzheimer's Disease Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to progressive memory loss and death. In the midst of biotech giants like Novartis, Pfizer, and Biogen working on treatments for Alzheimer's disease, emerging player LGVN is testing Lomecel-B as a potential treatment for AD based on the hypothesis that its multiple possible MOAs can simultaneously address multiple features of AD. Preclinical studies show that MSCs can potentially reduce AD-associated brain inflammation, improve the function of blood vessels in the brain, and reduce brain damage due to AD progression, and promoteregenerative responses! The company has completed a multicenter, randomized, placebo-controlled Phase 1 safety study of subjects with mild AD (n=33) designed to evaluate safety and tolerability, and to explore potential efficacy. This trial was supported by a Part the Cloud grant from the Alzheimer’s Association. Based on preliminary results, the company is initiating a larger Phase 2 study. If successful in clinical studies, Lomecel-B may prove to be a disease-modifying therapy for AD! HUGE NEWS In January 2022, the company opened enrollment for their Phase 2a clinical trial of Lomecel-B for the treatment of Alzheimer’s Disease! The Phase 2a study, supported by encouraging Phase 1 data announced in 2021, is designed to evaluate the safety of single and multiple administrations of two different doses of Lomecel-B compared to placebo in mild Alzheimer’s disease patients. Other endpoints include brain volumetry by MRI, biomarkers related to inflammatory and vascular systems, and various measures of cognitive function. The first patient has already been treated (the study has a target enrollment of 48 patients), and we intend to activate up to 12 clinical sites to facilitate enrollment. LGVN plans to provide updates on anticipated enrollment rates as additional sites are activated, and trial completion guidance. Further details about the trial design can be found on clinicaltrials.gov by entering trial identifier NCT05233774. The company has also submitted our Phase 1 results for publication in a peer-reviewed journal and anticipate acceptance and publication during the first half of 2022. “For Longeveron, 2021 was a year defined by effective execution, successful financings, and significant progress across our robust Lomecel-B pipeline of clinical trials. Since our IPO in February of last year, important progress has been made in advancing Lomecel-B into next phase trials, including initiation of Phase 2 trials in Alzheimer’s and Hypoplastic Left Heart Syndrome (HLHS), with the latter receiving both Orphan Drug and Rare Pediatric Disease designations from the FDA." "Additionally, we successfully closed a $20.5 million private placement of our common stock in the fourth quarter of 2021 to provide capital that we believe will be sufficient to support our ongoing research and operations into 2024. We anticipate 2022 to be another eventful year as we continue to work to demonstrate the potential therapeutic benefit of Lomecel-B across many life-threatening conditions.” Geoff Green, Chief Executive Officer at Longeveron The biotech space is so beaten down, several relative valuation metrics suggest it can move up anywhere from 24% to 155%, according to this recent analysis from [Bank of America!]( As prospects for the biotech sector heighten in 2022, LGVN is a company to keep your eyes on.... the company's therapy could potentially be a game-changer in treating several conditions with major markets! Start your research right away! Copyright 2022 © TopStockTips.com is owned and operated by TopStockTips Ltd. [Disclaimer and Privacy]( For more Information please contact Support@TopStockTips.com Company Address: Rua Frei Tome de Jesus, n18, 1dto., 1700-215 Lisboa, Portugal. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. This communication includes advertising material and PAID ADVERTISEMENTS provided to our subscribers. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by TopStockTips, Unipessoal Ltd. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TopStockTips” refers to TopStockTips, Unipessoal Ltd. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and the number of shares below. TopStockTips’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TopStockTips often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. This newsletter and TopStockTips Unipessoal Ltd is partially owned by the owner of TRADIGITAL MARKETING GROUP, INC. (D/B/A “TRADIGITAL IR”). OUR REPORTS ARE ADVERTORIALS AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR EMAIL LIST, AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE. PLEASE NOTE WELL: TRADIGITAL IR AND ITS EMPLOYEES ARE NOT REGISTERED INVESTMENT ADVISORS, BROKER-DEALERS, OR MEMBER(S) OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE, VIEWING OR USING YOU AGREE TO HOLD TRADIGITAL IR, ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES THAT WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. TRADIGITAL IR ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED OR IS AVAILABLE FROM PUBLIC SOURCES AND TRADIGITAL IR MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD, TRADIGITAL IR STRONGLY URGES YOU TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. TRADIGITAL IR’S FULL DISCLOSURE IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING TRADIGITAL IR'S WEBSITE, OR JOINING TRADIGITAL IR'S EMAIL OR TEXT LIST. FROM TIME TO TIME, TRADIGITAL IR WILL DISSEMINATE INFORMATION ABOUT A COMPANY VIA WEBSITE, EMAIL, SMS, AND OTHER POINTS OF MEDIA. BY VIEWING TRADIGITAL IR'S WEBSITE AND/OR READING TRADIGITAL IR'S EMAIL OR TEXT NEWSLETTER YOU ARE AGREEING ----> HTTPS://TRADIGITALIR.COM/DISCLAIMER-TMG/. ALL POTENTIAL PERCENTAGE GAINS DISCUSSED IN ANY COMMUNICATIONS ARE BASED ON CALCULATIONS FROM THE LOW TO THE HIGH OF THE DAY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. IN COMPLIANCE WITH SECTION 17(B) OF THE SECURITIES ACT WE ARE DISCLOSING THAT WE HAVE BEEN COMPENSATED A FEE PURSUANT TO AN AGREEMENT BETWEEN TRADIGITAL AND LONGEVERON INC. TRADIGITAL WAS HIRED FOR A PERIOD BEGINNING APRIL 2021 AND ENDING OCTOBER 2021 TO PUBLICLY DISSEMINATE INFORMATION ABOUT LONGEVERON INC., VIA WEBSITE, EMAIL, AND SMS. WE WERE PAID TEN THOUSAND USD EACH MONTH, VIA ACH. WE OWNED TWELVE THOUSAND RESTRICTED COMMON SHARES OF LONGEVERON INC., WHICH WERE ELIGIBLE FOR SALE ON 10/1/2021. WE SOLD THIS ENTIRE POSITION AS OF 3/28/2022. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D. TRADIGITAL IR IS COMPLIANT WITH THE CAN-SPAM ACT OF 2003. TRADIGITAL IR DOES NOT OFFER INVESTMENT ADVICE OR ANALYSIS, AND TRADIGITAL IR FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP, SMALL-CAP, AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTOR'S INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS, OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH THE USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTES; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS IN PREPARING THIS PUBLICATION, TRADIGITAL IR HAS RELIED UPON INFORMATION SUPPLIED BY ITS CLIENTS, AS WELL AS ITS CLIENTS’ PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CAN NOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED ON THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, TRADIGITAL IR AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES, AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. TRADIGITAL IR IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS TRADIGITAL IR RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM, OR ITS STRUCTURE. TRADIGITAL IR IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION, OR FINRA 18 R. Frei Tomé de Jesus Lisboa Lisboa 1700 PORTUGAL [Unsubscribe]( | [Change Subscriber Options](